Investigational drug · Phase 2
EPI-321
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Facioscapulohumeral Muscular Dystrophy.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "EPI-321"
First trial start
2025
May 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EPI-321", any sponsor or status.
Conditions studied
As listed on its trial records.
- Facioscapulohumeral Muscular Dystrophy
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "EPI-321" as an intervention, largest first.
- A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyActive, not recruiting
Epicrispr Biotechnologies, Inc.Industry
NCT06907875 · 12 participants (planned) · Start May 8, 2025 · Primary completion Jul 7, 2027
Drug: EPI-321 · For: Facioscapulohumeral Muscular Dystrophy
Sites: Los Angeles, California; Atlanta, Georgia; Baltimore, Maryland · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Epigenetic editing approaches maturity: AI-driven precision design, delivery innovation, and the road to clinical translation.
Chang S, Lu D, Jin Y, et al. · Clin Epigenetics 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.